Key Takeaways
- A biopsy is the procedure that obtains tissue; pathology is the laboratory and medical interpretation of that tissue. A second review often re-examines the same material rather than repeating the biopsy.
- Differences can arise from limited sampling, a larger later specimen, tissue handling, additional stains or molecular tests, updated classification criteria, tumor heterogeneity or specialist interpretation.
- “Different wording” is not always a true conflict. Ask whether the change affects cancer type, grade, stage-related features, biomarker status or treatment.
- Send the original report, H&E and special-stain slides, paraffin block or unstained slides when requested, operative/biopsy details, imaging and molecular reports. A translated summary alone is insufficient.
- Tissue is finite. Before cutting a block for repeated testing, ask the pathologist to make a tissue-allocation plan that preserves material for clinically necessary biomarkers.
- If reports disagree in a treatment-changing way, arrange pathologist-to-pathologist reconciliation and a signed final/addendum report. Do not let a coordinator silently choose the more reassuring answer.
Content
Two pathology reports can use different words without describing different diseases. They can also disagree in a way that changes surgery, drug selection or whether a person is considered to have cancer at all. The first task is to classify the difference—not to vote for a favorite laboratory.
Biopsy, pathology and pathology review are different events
Biopsy obtains a tissue sample by needle, endoscopy or surgery. Pathology examination processes the sample, looks at tissue architecture and cells, may add immunohistochemistry or molecular tests, and issues a diagnosis. Pathology review asks another pathologist or institution to re-evaluate existing slides/blocks, sometimes with additional work.
NCI describes the pathology report as the document that records specimen identity and acquisition, gross and microscopic findings, final diagnosis and—when relevant—grade, margins, lymph nodes and ancillary test results [1]. It also confirms that patients seeking a second opinion generally need slides and/or a paraffin block from the original laboratory [1].
A review is not automatically evidence that the first pathologist made a mistake. It is a controlled re-evaluation of the evidence available.
First ask: are both reports examining the same specimen?
Put these fields side by side:
- patient full name and another identifier;
- accession/case number;
- collection date;
- body site, side and exact procedure;
- specimen label and number of containers;
- core biopsy, fine-needle material, excision or resection;
- treatment before each specimen;
- block/slide identifiers reviewed.
A tiny core and a later resection are not equivalent. The core may sample one edge of a heterogeneous tumor; the resection shows more architecture, invasion, margins and lymph nodes. A metastatic site may not look or test exactly like the primary tumor. Treatment may also change morphology and biomarkers over time.
If identifiers or sites do not match, pause clinical use until the laboratories resolve specimen identity. Do not solve a potential labeling problem with translation.
Five reasons a later report may differ
1. Sampling
The biopsy may contain little tumor, crush artifact, necrosis or tissue from a non-representative area. A later sample may show a component not captured before. NCI notes that insufficient tumor tissue can prevent biomarker testing and that not all cancer cells necessarily share the same biomarkers [2].
2. Processing and technical quality
Fixation time, decalcification, section thickness, staining quality, antigen preservation, nucleic-acid quality and the proportion of tumor cells can affect what can be seen or measured. A bone specimen exposed to harsh decalcification, for example, may be less suitable for some molecular or protein tests.
China’s current pathology quality indicators include immunohistochemical slide quality, diagnostic timeliness and other process measures, reflecting that technical preparation is part of diagnostic quality [4].
3. Additional information
The reviewing center may receive imaging, surgery notes, a prior tumor, new immunostains, FISH, sequencing or infection studies not available originally. The diagnosis can become more specific because the evidence set changed.
4. Classification and thresholds
Tumor names, grading systems, molecular categories and biomarker scoring rules evolve. Two reports may follow different editions, antibody clones, platforms or cutoffs. The reviewing pathologist should state the classification or scoring system used when it matters.
5. Interpretation
Some lesions sit near a diagnostic boundary or are rare. A subspecialist may weigh morphology and stains differently. Genuine interpretive disagreement is possible even when both laboratories worked carefully.
Not every change has the same clinical weight
Ask the reviewing pathologist to classify the discrepancy:
- Terminology only: different wording, same practical diagnosis.
- Refinement: a more specific subtype without changing current treatment.
- Ancillary-test change: biomarker or molecular result differs and may affect a drug or trial.
- Major diagnostic change: benign versus malignant, different lineage, materially different grade, primary versus metastasis, or a feature that changes surgery/systemic therapy.
- Unresolved/insufficient: available material cannot answer the question.
The clinician then states what decision changes. A report should not be called “more accurate” merely because it is longer or from a famous hospital.
Build the review package before shipping tissue
The receiving pathology service should issue a specimen list and shipping instructions. A complete package may include:
- original signed pathology report and all addenda;
- gross description and specimen map if separate;
- representative H&E slides;
- existing immunohistochemistry/special-stain slides and result table;
- requested paraffin blocks or specified unstained slides;
- cytology smears/cell block where relevant;
- molecular/FISH/flow-cytometry reports, including method, specimen/block and quality metrics;
- biopsy/operation note and exact anatomical site;
- relevant CT/MRI/PET images and radiology report;
- treatment history and the precise consultation question.
NCI consultation instructions similarly request outside reports, representative H&E, existing immunostains and paraffin material [5]. Confirm whether the institution accepts originals, recut slides, blocks or validated digital slides. Do not send irreplaceable originals without a receipt and return plan.
Keep chain of custody visible
Record:
- what left the original laboratory;
- each slide/block identifier;
- date, courier and tracking;
- receiving person/service;
- condition on receipt;
- what was cut or consumed;
- what will be returned and when.
Use institution-to-institution shipping when possible. Paraffin blocks and slides are medical specimens, not ordinary souvenirs; cross-border courier, customs and temperature/packaging requirements should be confirmed before dispatch. Keep scanned reports and photographs of slide/block labels, but protect patient identifiers.
Protect finite tissue
A paraffin block can support diagnosis, immunostains and molecular testing, but every recut consumes tissue. Before sending the only tumor-rich block to several laboratories, ask the pathologist to estimate:
- tumor amount and percentage;
- remaining material;
- tests required now versus optional later;
- whether unstained slides can be cut once and allocated;
- whether another block or newer biopsy is better;
- priority if tissue is insufficient.
NCI emphasizes that biomarker testing may fail when tumor tissue is insufficient and that an older result may no longer represent a recurrent cancer [2]. “Test everything” can leave no material for the test that actually determines treatment.
Biomarker disagreements need method-level review
For ER/PR/HER2, PD-L1, mismatch-repair proteins, ALK/ROS1, EGFR and other markers, compare more than positive/negative:
- specimen, site, date and whether collected before/after treatment;
- tumor-cell content and adequacy;
- assay platform, antibody clone or sequencing panel;
- scoring system and cutoff;
- internal/external controls;
- exact score, allele fraction, copy number or read quality;
- whether the result was confirmed by another method.
Tumor heterogeneity and evolution can make two valid samples differ. A new biopsy is not automatically necessary; the clinical team weighs safety, timing, remaining tissue, liquid-biopsy limitations and whether the result would change therapy.
Close a major discrepancy with a named final diagnosis
When reports conflict materially:
- ask each pathologist to specify the reviewed material and basis;
- share missing stains, images and clinical context in both directions;
- request direct pathologist-to-pathologist discussion or a subspecialty/tumor-board review;
- identify whether more testing or new tissue is necessary;
- issue a signed addendum or consultation report stating the reconciled diagnosis and remaining uncertainty;
- have the treating clinician document which report governs treatment and why.
Do not begin an irreversible treatment while a diagnosis-changing discrepancy remains hidden in email, unless urgency requires action and the team explicitly documents the uncertainty and rationale.
Read the final report as a structured answer
Confirm that it states, when applicable:
- specimen/site/procedure;
- histologic type and grade;
- invasion, margins and lymph nodes for resections;
- immunohistochemical and molecular results with methods/scores;
- adequacy limitations;
- comparison with prior pathology;
- final diagnosis and comment;
- pathologist name and report/addendum date.
Pathology is often the definitive basis for cancer diagnosis, but it still belongs in an integrated clinical picture. NCI notes that pathology, imaging and other tests are reviewed together for treatment planning [1].
Medical disclaimer: This guide provides general education. Tissue selection, ancillary testing and resolution of diagnostic discrepancies must be led by qualified pathologists and the treating multidisciplinary team.
FAQ
Does a second pathology review require another biopsy?
Usually not at first. The reviewing pathologist can examine existing slides and blocks. A new biopsy is considered only if the material is insufficient, no longer representative or unable to answer a treatment-changing question.
Why can a biopsy and surgical specimen have different diagnoses?
A biopsy samples only part of a lesion, while a resection shows more tissue and architecture. Heterogeneity, treatment effect and tissue quality can reveal features not present in the smaller sample.
Should I send slides or the paraffin block?
Follow the receiving laboratory’s written list. It may request H&E and stained slides, unstained slides, a selected block or all relevant material. Never send the only block without tracking, tissue planning and a return agreement.
Which report should the oncologist use if they conflict?
There should be a formal reconciliation based on the actual material, methods and clinical context, ideally with pathologist-to-pathologist discussion. The treating team should document the final governing diagnosis and any uncertainty.
Can molecular results change even when both tests are correct?
Yes. Different tumor areas or time points may contain different biomarkers, and treatment can select new clones. Assay method, tumor content and thresholds also matter, so the full technical details must be compared.
Sources
- US National Cancer Institute: Surgical Pathology Reports and Second Opinions
- US National Cancer Institute: Biomarker Testing for Cancer Treatment
- US National Cancer Institute: Improving Quality of Cancer Biopsy Specimens
- National Health Commission of China: Pathology Quality Indicators (2024)
- US National Cancer Institute: Pathology Consultation Submission Instructions